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1. Introduction 
Epidermodysplasia verruciformis (EV; MIM#226400) is a genodermatosis characterized by 
susceptibility to epidermodysplasia verruciformis-human papillomavirus (EV-HPV) 
infections which leads to early development of disseminated pityriasis versicolor-like and 
flat wart-like lesions [1]. The disease was first described by Lewandowski and Lutz in [1]. 
Approximately half of all patients with EV will develop cutaneous malignancies, 
predominately Bowen’s type carcinoma in situ and invasive squamous cell carcinomas that 
occur mainly on sun-exposed areas in the fourth or fifth decade of life [2-4].Thus, EV is in 
essence a genetic cancer of viral origin, and could also be regarded as a model of cutaneous 
HPV oncogenesis [5, 6]. In general, EV shows an autosomal recessive pattern of inheritance 
[7]. The EV loci were mapped to chromosome 2p21-p24 (EV2) and 17q25 (EV1) [8], 
respectively. In the EV1 interval, 2 adjacent related genes, EVER1 and EVER2, were 
identified in 2002 [9]. EVER proteins are members of transmembrane channel-like (TMC) 
family. They are encoded by 8 genes (TMC1-8). EVER1 and EVER2 correspond to TMC6 and 
TMC8, respectively [10, 11]. Therefore the recent literature has focused on the mutation 
finding the culpable gene. Clinical and histologic findings, EV-HPV, cutaneous oncogenesis, 
and genetics will be briefly reviewed. 
2. Clinical and histologic findings 
Classic EV begins during childhood with highly polymorphic cutaneous lesions, including 
pityriasis versicolor-like macules (Figure 1), flat wart-like papules (Figure 2), and lesions 
resembling seborrheic keratoses that can undergo malignant transformation [2, 4, 6, 12, 13]. 
Approximately half of all patients with EV will develop cutaneous malignancies, 
predominately Bowen’s type carcinoma in situ and invasive squamous cell carcinomas 
(SCCs) that occur mainly on sun-exposed areas in the fourth or fifth decade of life [2, 4, 6, 
12]. Development of malignant transformation is usually associated with HPV-5 and -8. 
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However, the mechanism of carcinogenesis induced by EV-related HPV types is not clear in 
contrast to the other oncogenic HPVs, these do not seem to need integration into the host’s 
genome [14]. EV patients have impaired cell-mediated immunity (CMI) [15–20]. Decreased 
T-lymphocyte counts and CD4/CD8 ratios and a reduced T-cell responsiveness to mitogens 
were found in some patients. 
 
Figure 1. Pityriasis versicolor-like macules 
 
Figure 2. Flat wart-like papules 
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There is an indication of EV-like disease being a result of exogenous immunodeficiency in 
HIV infection and in the patients with immunodeficiency states(e.g. following renal 
transplantation, in systemic lupus erythematosus or Hodgkin’s disease ) [21-24].This form 
has been named  “acquired epidermodysplasia verruciformis” [25]. 
Histopathologically, lesions demonstrate stereotypical enlarged keratinocytes in upper 
epidermis with gray-blue cytoplasm, enlarged round nuclei with pale chromatin, and one or 
multiple nucleoli (Figure 3).The Immunohistochemistry findings showed the HPV antigens  
 
Figure 3. Enlarged keratinocytes in upper epidermis with gray-blue cytoplasm (haematoxylin and 
eosin) 
 
Figure 4. HPV antigens using anti-HPV monoclonal antibody are demonstrated 
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using anti-HPV monoclonal antibody (K1H8) were located in the cell nucleus of the third 
superior of the epithelium, observing the brownish-gold colored precipitins caused by 
cromogen in the nucleus of these cells (Figure 4). In in situ hybridization (ISH) EV HPV-5 
DNA was detected in upper epidermis, abundant in parakeratotic cells (Figure 5) [26].In 
electron microscopy, The nuclei are clarified with maeginated chromatin, and crystalline 
viral particles are present in nucleoplasm and in the prominent nucleoli (Figure 6). Under an 
electron microscope, HPV5 virions purified from pooled scales of EV patients and virus-like 
particles (VLP) assembled from a purified recombinant baculoviruses expressing the L1 
major capsid protein of HPV5 were observed(Figure 7) [27]. 
 
 
Figure 5. HPV-5 DNA is demonstrated in the nuclei of spinous and granular cells (ISH) 
 
Figure 6. Crystalline viral particles in electron microscopy 
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Figure 7.  
3. EV-HPV infection 
The disease is a generalized HPV infection, resulting from a genetically determined 
susceptibility of the skin to infection with particular types of HPV [28]. Papillomaviruses 
(PVs) are small, non-enveloped, double-stranded DNA viruses, which can infect mucosal or 
cutaneous epithelia. At least 118 distinct papillomavirus (PVs) types, more than 100 of them 
isolated from humans, have been completely described. The human papillomavirus 
genotypes are distributed across 5 genera. The five genera encompassing human PV are 
called alpha (both mucosal and cutaneous types), beta, gamma, mu and nu (exclusively 
cutaneous types)[29]. Genera are divided into species and types on the basis of nucleotidic 
sequence comparisons. Members of species have similar biological or pathological properties 
(Table 1) [29-31]. EV HPV genotypes constitute the beta-papillomavirus genus and are 
distributed into five species [29, 31], mainly beta 1, comprising the potentially oncogenic types 
5, 8, 14, 20, and 47 [2], and beta 2(Table 1). Beta PV are ubiquitous in the general population 
and frequently establish themselves already during the first weeks of life. Hair follicles are 
regarded as natural reservoir. About 25% of beta PV detected in adults persist for at least 9 
months. Due to very low virus production, seroconversion against beta PV starts sluggishly. 
Hyperproliferation of keratinocytes in psoriasis patients or after severe burn stimulates virus 
replication. Massive virus replication only occurs in EV patients, associated with the induction 
of disseminated skin lesions with a high risk of malignant conversion. 
Papillomaviruses share the same genetic organization [32]. At least eight open reading 
frames (ORFs) are located on the same DNA strand, downstream of a noncoding, long 
regulatory region containing transcriptional and replication regulatory elements. The E1 and 
E2 ORFs encode proteins involved in the replication of the viral genome (E1, E2), the 
segregation of the viral genome in dividing cells (E2) and in the regulation of its 
transcription (E2). The E6 and E7 proteins interact with cell cycle regulatory proteins and are 
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required for promoting the S-phase and for inhibiting apoptosis in resting and in terminally 
differentiating keratinocytes. The E6 and E7 proteins of potentially oncogenic genotypes 
induce genetic and chromosomal instability. The E5 protein displays growth promoting 
properties. The L1 and L2 ORFs encode the major (L1) and minor (L2) capsid proteins [32]. 
The genomes of EV HPVs are characterized by a shorter size and a specific organization of 
the regulatory region, the lack of an E5 ORF [33], and a great intratype genetic heterogeneity 
[34, 35]. 
 
Genus Spiecies Human papillomavirus(HPV) 
β-
papillomavirus 
β-１ HPV-5, -8, -14,-12, -19, -20, -21, -24, -25, -36, -47, -93, -98, -99, -105, 
-118, -124 
 
β- 2 HPV-9, -15, -17, -22, -23, -37, -38, -80, -100, -104, -107, -110, -111, 
-113, -120, -122, -151 
β- 3 HPV-49, -75, -76, -115 
β- 4 HPV-92 
  β- 5 HPV-96, -150 
Table 1. HPV-Type in 5 species of the genusβ-Papillomavirus 
4. Cutaneous oncogenesis –EV and non-EV 
Highly sensitive PCR methods based on various sets of primers have been designed to 
detect a broad range of known EV HPVs or putative novel EV HPV-related genotypes [36]. 
This has brought a wealth of information about the epidemiology and biology of these 
viruses [37, 38]. EV HPVs were found to be highly prevalent in the normal skin of healthy 
adults [39–41] and shown to be acquired very early in infancy [42]. An impressive diversity 
of putative novel beta PV has been disclosed [41]. 
Nonmelanoma skin cancer (NMSC) is the most common form of malignancy in fair-skinned 
populations. The role of ultraviolet radiation as an environmental carcinogen, capable of 
inducing mutations in both genomic and mitochondrial DNA and thereby being a causative 
agent in the development of NMSC, is well established [43]. Although the importance of 
HPV in cervical SCC is well-documented, the role of HPV in cutaneous SCC is controversial 
[43, 44]. EV may offer a model for cutaneous SCC [28]. In both their benign and malignant 
lesions, a broad spectrum of predominantly beta PV were found with a combined 
prevalence of 90% for HPV 5 and 8 in SCC [2, 6] . In lesions of EV patients, the viral genome 
usually persists extrachromosomally and in high copy numbers (100–300 copies per cell 
equivalent) [45-47]. High viral loads have also been found in hair bulbs from plucked 
eyebrows of these patients [47]. In both immunocompetent and immunosuppressed non-EV 
patients these viruses are also frequently found; however, only very low copy numbers 
(usually below one copy per cell) were detected in actinic keratosis, SCC, basal cell 
carcinoma, and perilesional skin [48]. It has been shown that beta PV are transcriptionally 
active in benign and malignant lesions of EV patients [49, 50] and also in 3 of 4 actinic 
keratosis and 5 of 18 SCC of immunosuppressed non-EV patients [51, 52]. 
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5. Genetics 
As early as 1933, Cockayne postulated that EV was probably transmitted by a recessive gene 
[53] and an autosomal recessive mode of transmission was first proposed in 1972 [54]. 
Inspections of EV patient pedigrees have revealed that a large portion (approximately 10% 
in a review of 147 case reports [7]) are born to consanguineous parents. Additionally, 
because the proportion of EV siblings in families has approached 30% [55], the mode of EV 
transmission has been thought to be autosomal recessive. An X-linked recessive inheritance 
has also been reported [56], however, pointing to a possible genetic heterogeneity of the 
disease [57]. Recent studies have advanced our understanding of the genetic defects carried 
by EV patients. A genome-wide linkage study was performed recently on consanguineous 
EV families (first-cousin marriages), using the homozygosity mapping approach that 
represents a simple and efficient strategy to map rare human recessive traits [8, 58].The two 
susceptibility loci EV1 and EV2 were first mapped to chromosomes 17q25 from the study of 
families from Algeria and Colombia and 2p21-p24 from French family, respectively, in 2000 
[8]. Since those initial findings were reported, specific mutations in the genes EVER1 and 
EVER2, both located within the EV1 locus, have been discovered. Ramoz et al. [9] first 
described two highly conserved nonsense mutations in the EVER1 and EVER2 genes of all 
affected individuals in two Algerian and two Colombian consanguineous families. 
Subsequently, novel mutations in these genes were identified in patients of multiple races 
and nationalities [59-68,9]. In all, 15 truncating, loss-of-function mutations caused by several 
mechanisms (nonsense mutation, single nucleotide deletion, splice site mutation, and exon 
deletion) have been identified, eight in EVER1 and seven in EVER2. The TMC 
(transmembrane channel-like) gene family comprises eight genes (TMC1 to8) [10, 11]. 
EVER1 and EVER2 are identical to the TMC6 and TMC8 genes, respectively. Although the 
proteins encoded by the EVER genes have been shown to localize in the endoplasmic 
reticulum with features of integral membrane proteins, the exact function in development of 
persistent HPV infections has not yet been revealed [9,59]. It has been hypothesized that 
these proteins act as restriction factors for EV specific HPVs in keratinocytes, and that EV 
represents a primary deficiency of intrinsic immunity against certain papillomaviruses[57]. 
Although most EV patients studied (75.6%, according to collaborative efforts reported in the 
review by [57]) have been found to have homozygous mutations in EVER1 or EVER2, this 
still leaves a significant number of EV patients with unexplained inheritance patterns. Three 
cases have reported genetic analysis of EV patients in whom EVER1 or EVER2 mutations 
were lacking [69-71]. In a recent case-control study, EVER2 polymorphisms were associated 
with SCC development [66]. The exact function of TMC proteins still unclear, but it is 
assumed that they belong to a new group of channels or iron transporters and could be 
involved in signal transduction [10, 11]. EVER1/TMC6 and EVER2/TMC8 proteins are 
located in the endoplasmic reticulum of keratinocytes, where they form a complex with zinc 
transporter-1 (ZnT-1). EVER1/TMC6 and EVER2/TMC8 act as modifiers of zinc transporter 
ZnT-1. Potentially, EVER proteins mediate the protection against oncogenic HPV via 
regulation of cellular zinc balance [72, 73]. A mutation in the EVER1 or EVER2 gene might 
block the formation of the EVER/ZnT-1 complex, which would allow the expression of 
transcription factors (e.g.AP-1), thus promoting viral replication [14].  
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6. Conclusion 
In EV patients there is a strong association between beta HPV infection and NMSC. This 
predisposition is genetically determined by mutations of the 2 genes EVER1/TMC6 and 
EVER2/TMC8. However, only in 75% of EV patients, an EVER mutation has been found. 
This suggests other genes are involved. A second EV susceptibility locus (EV2) on 
chromosome 2p21-p24 by autosomal recessive inheritance is assumed [8]. X-linked recessive 
inheritance [56] and autosomal dominant transmission have been reported [71]. 
Identification of additional genes associated with EV should provide more clues for the 
understanding of host defences against papillomaviruses. 
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